HPV Self-sampling Cost Effectiveness Model

Cost-effectiveness model to understand the conditions under which harms will outweigh benefits for the offer of HPV self-sampling in the UK.

Cost-effectiveness model to understand the conditions under which harms will outweigh benefits for the offer of HPV self-sampling in the UK.

Deliverables will include the following:

• Model Specifications: Development of a model to determine the conditions under which the introduction of self-sampling in the cervical screening programme provides the most benefits in terms of clinical outcomes for women and cost-effectiveness for the programme.
• Cost effectiveness model: Running of model and analysis of cost-effectiveness.
• Model Technical Report: Interim report(s) by Spring 2025, to feed into the ISE design process.
• Model: Final report(s) in Spring 2026 clearly outlining model type, analytical approach, assumptions, uncertainties, results, and discussion, including implications to policy.
• It is expected that the final paper is published in a peer-reviewed journal to highlight the high-quality and robust work required.
• Transfer of the model’s outputs to the UK NSC. Additional information: 1.1. For avoidance of doubt THIS IS NOT a call for competition.

This is a market consultation. The purpose is to advise suppliers of the forthcoming Department of Health and Social Care (DHSC) procurement and seek feedback from potential bidders and existing providers that may inform the final specifications and/or procurement approach to the services.